Journal article
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8 T Cells
M Braun, AR Aguilera, A Sundarrajan, D Corvino, K Stannard, S Krumeich, I Das, LG Lima, LG Meza Guzman, K Li, R Li, N Salim, MV Jorge, S Ham, G Kelly, F Vari, A Lepletier, A Raghavendra, S Pearson, J Madore Show all
Immunity | CELL PRESS | Published : 2020
Abstract
Braun et al. find that CD155 on tumor cells drives the proteasomal degradation of the activating receptor CD226 on tumor-infiltrating CD8+ T cells, thus promoting immune evasion and resistance to cancer immunotherapy.
Grants
Awarded by Amgen
Funding Acknowledgements
We would like to thank L. Town, A. Zaharia, K. Elder, P. Collins, M. Flynn, and S. Ng as well as the Core facilities at QIMR Berghofer for excellent technical assistance. We are grateful to Dr W.Y. Langdon from the University of Western Australia for providing the Cbl-b mutant mouse. The project was supported by the BioBank Core Facility of the University Hospital Bonn, Germany. M.B. is supported by a scholarship of the Dr. Mildred Scheel Stiftung fuer Krebsforschung of the Deutsche Krebshilfe. T.B. was supported by a NHMRC Early Career Research Fellowship (1138757) and project grant (1124690) and a Melanoma Research Alliance Young Investigator grant (693786). M.J.S. was supported by a NHMRC Investigator Award (1173958) and program grant (1132519). M.J.S. and I.D. were supported by a Cancer Council Queensland project grant (1157048). A.V. is supported by grants from the Canadian Institutes of Health Research (MT-14429, MOP-82906, FDN-143338) and holds the Canada Research Chair on Signaling in the Immune System. M.H. was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) within GRK 2168. M.E. was supported by a scholarship within GRK 2168. M.H. and M.G. are funded by the DFG under Germany's Excellence Strategy (EXC2151-390873048). J.S.W. is supported by a NHMRC fellowship, the Melanoma Institute Australia, the New South Wales Ministry of Health, NSW Health Pathology, Cancer Institute NSW, and the Ainsworth Foundation. R.A.S and G.V.L. are supported by NHMRC Practitioner Fellowship. G.V.L. is supported by the University of Sydney Medical Foundation and Melanoma Institute Australia. This work was funded by the National Breast Cancer Foundation Australia (IIRS-18-159) and NHMRC (APP1185907) to A.M. O.T.P. is supported by a grant from the Cancer Research Center of the University Hospital and the University of Zurich. L.F. is supported by a grant from the Swiss National Science Foundation (PP00P3_157448).